File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: Report of a phase II study

TitleCombination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: Report of a phase II study
Authors
KeywordsCisplatin
Gemcitabine
Metastasis
Nasopharyngeal carcinoma
Phase II
Recurrence
Issue Date2002
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
Annals Of Oncology, 2002, v. 13 n. 8, p. 1252-1258 How to Cite?
AbstractBackground: To evaluate the efficacy and toxicity of combination gemcitabine plus cisplatin (GC) chemotherapy in metastatic or recurrent nasopharyngeal carcinoma (NPC). Patients and methods: Forty-four patients of Chinese ethnicity with metastatic or recurrent NPC received ambulatory GC chemotherapy every 28 days (gemcitabine 1000 mg/m 2 days 1, 8 and 15; cisplatin 50 mg/m 2 days 1 and 8). There were 40 male and four female patients with a mean age of 47.4 years. More than half (54.5%) of the patients had received either prior platinum-based chemotherapy and/or radiotherapy to target lesions. Results: There were nine complete responses and 23 partial responses in the 44 patients, achieving an overall response rate of 73% (78% for the 41 assessable patients). The mean duration of response was 5.3 months. Improved subjective symptom-control scores were found in 78% of patients with pre-existing symptoms, while 64% of patients experienced improved general well-being scores. Toxicity was mainly hematological: grade III/IV anemia, granulocytopenia and thrombocytopenia were found in 11, 37 and 16% of cycles, respectively. With a median follow-up of 17.2 months, 62% survived 1 year while 36% were alive and progression free. Conclusions: Gemcitabine plus cisplatin chemotherapy offers a satisfactory overall response rate, subjective patient improvement and safety profile for metastatic and recurrent NPC.
Persistent Identifierhttp://hdl.handle.net/10722/78057
ISSN
2015 Impact Factor: 9.269
2015 SCImago Journal Rankings: 4.362
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFoo, Wen_HK
dc.contributor.authorNgan, RKCen_HK
dc.contributor.authorLaw, CKen_HK
dc.contributor.authorYiu, HHYen_HK
dc.contributor.authorTse, KCen_HK
dc.contributor.authorLau, WHen_HK
dc.contributor.authorYau, Sen_HK
dc.contributor.authorCheung, FYen_HK
dc.contributor.authorChan, TMen_HK
dc.contributor.authorKwok, CHen_HK
dc.contributor.authorChiu, CYen_HK
dc.contributor.authorAu, SKen_HK
dc.date.accessioned2010-09-06T07:38:41Z-
dc.date.available2010-09-06T07:38:41Z-
dc.date.issued2002en_HK
dc.identifier.citationAnnals Of Oncology, 2002, v. 13 n. 8, p. 1252-1258en_HK
dc.identifier.issn0923-7534en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78057-
dc.description.abstractBackground: To evaluate the efficacy and toxicity of combination gemcitabine plus cisplatin (GC) chemotherapy in metastatic or recurrent nasopharyngeal carcinoma (NPC). Patients and methods: Forty-four patients of Chinese ethnicity with metastatic or recurrent NPC received ambulatory GC chemotherapy every 28 days (gemcitabine 1000 mg/m 2 days 1, 8 and 15; cisplatin 50 mg/m 2 days 1 and 8). There were 40 male and four female patients with a mean age of 47.4 years. More than half (54.5%) of the patients had received either prior platinum-based chemotherapy and/or radiotherapy to target lesions. Results: There were nine complete responses and 23 partial responses in the 44 patients, achieving an overall response rate of 73% (78% for the 41 assessable patients). The mean duration of response was 5.3 months. Improved subjective symptom-control scores were found in 78% of patients with pre-existing symptoms, while 64% of patients experienced improved general well-being scores. Toxicity was mainly hematological: grade III/IV anemia, granulocytopenia and thrombocytopenia were found in 11, 37 and 16% of cycles, respectively. With a median follow-up of 17.2 months, 62% survived 1 year while 36% were alive and progression free. Conclusions: Gemcitabine plus cisplatin chemotherapy offers a satisfactory overall response rate, subjective patient improvement and safety profile for metastatic and recurrent NPC.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_HK
dc.relation.ispartofAnnals of Oncologyen_HK
dc.rightsAnnals of Oncology. Copyright © Oxford University Press.en_HK
dc.subjectCisplatinen_HK
dc.subjectGemcitabineen_HK
dc.subjectMetastasisen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectPhase IIen_HK
dc.subjectRecurrenceen_HK
dc.titleCombination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: Report of a phase II studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0923-7534&volume=13&issue=8&spage=1251&epage=1258&date=2002&atitle=Combination+gemcitabine+and+cisplatin+chemotherapy+for+metastatic+or+recurrent+nasopharyngeal+carcinoma:+report+of+a+phase+II+studyen_HK
dc.identifier.emailChan, TM:dtmchan@hku.hken_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/annonc/mdf200en_HK
dc.identifier.scopuseid_2-s2.0-0036668667en_HK
dc.identifier.hkuros81923en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036668667&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1252en_HK
dc.identifier.epage1258en_HK
dc.identifier.isiWOS:000177641000016-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridFoo, W=7003318564en_HK
dc.identifier.scopusauthoridNgan, RKC=6701397734en_HK
dc.identifier.scopusauthoridLaw, CK=26532827800en_HK
dc.identifier.scopusauthoridYiu, HHY=6603694447en_HK
dc.identifier.scopusauthoridTse, KC=16201492900en_HK
dc.identifier.scopusauthoridLau, WH=7402933278en_HK
dc.identifier.scopusauthoridYau, S=7202478327en_HK
dc.identifier.scopusauthoridCheung, FY=35910607100en_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.scopusauthoridKwok, CH=7102029126en_HK
dc.identifier.scopusauthoridChiu, CY=7402303685en_HK
dc.identifier.scopusauthoridAu, SK=7005457822en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats